Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001422 · ClinicalTrials.gov registry record · Phase 2
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
A Phase 2 study, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00001422 is a Phase 2 study that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 20 participants.
The verdict
NCT00001422, a Phase 2 study, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic drug.
Interventions
- DRUG fludarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1995-06 |
| Est. Completion | 2000-04 |
| Phase | Phase 2 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001422
The ClinicalTrials.gov registry entry for NCT00001422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fludarabine is the first listed.
NCT00001422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001422 about?
NCT00001422 is a clinical study titled "A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis". This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic drug.
What is the current status of trial NCT00001422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1995-06. Estimated completion is 2000-04.
What interventions are being tested in trial NCT00001422?
The interventions under investigation include: fludarabine (DRUG).
Who is sponsoring clinical trial NCT00001422?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.